Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus BSC Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy

Next Previous
Trial Profile

A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus BSC Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Regorafenib (Primary)
  • Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms CORRECT
  • Sponsors Bayer; Bayer HealthCare

Most Recent Events

  • 06 Jun 2023 Results of Matching-adjusted indirect treatment comparison assessing the efficacy and safety of sotorasib with standard of care trifluridine/tipiracil and regorafenib as monotherapy treatments using data from NCT01607957, NCT01103323 and NCT03600883 trials, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
  • 02 Jul 2022 Results of a network analysis of data pooled from 3 global (ReDOS, CORRECT, RECOURSE) and 3 Asian (TERRA, Yoshino 2012, and CONCUR) studies assessed the impact of regorafenib dose optimization on clinical outcomes compared to best supportive care and TAS-102 in the treatment of relapsed/refractory metastatic colorectal cancer presented at the 24th World Congress on Gastrointestinal Cancer
  • 22 Jan 2022 Results of a pooled analysis (NCT02122913, NCT02637687, NCT02576431, NCT01607957 and NCT01103323 )comparing the expected life-years and quality-adjusted life-years for metastatic CRC patients eligible to receive larotrectinib, regorafenib or trifluridine/tipiracil.presented at the 2022 Gastrointestinal Cancers Symposium

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top